Combination of radiosurgery and immunotherapy in brain metastases: balance between efficacy and toxicities

Concurrent administration of immune checkpoint inhibitors and single fraction stereotactic radiosurgery in patients with non-small cell lung cancer, melanoma, and renal cell carcinoma brain metastases is not associated with an increased risk of radiation necrosis over non-concurrent treatment: An international multicenter study of 657 patients

(2023) Eric J. Lehrer et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

How many brain metastases can be treated with stereotactic radiosurgery before the radiation dose delivered to normal brain tissue rivals that associated with standard whole brain radiotherapy?

(2023) Stewart J. Becker et al.   Journal of Applied Clinical Medical Physics

SAFESTEREO: phase II randomized trial to compare stereotactic radiosurgery with fractionated stereotactic radiosurgery for brain metastases

(2023) J. A. Crouzen et al.   BMC CANCER

The abscopal effect: inducing immunogenicity in the treatment of brain metastases secondary to lung cancer and melanoma

(2023) Jovanna A. Tracz et al.   JOURNAL OF NEURO-ONCOLOGY

Optimal timing and sequence of combining stereotactic radiosurgery with immune checkpoint inhibitors in treating brain metastases: clinical evidence and mechanistic basis

(2023) Wentao Tian et al.   Journal of Translational Medicine

Time interval from diagnosis to treatment of brain metastases with stereotactic radiosurgery is not associated with radionecrosis or local failure

(2023) Justin Leu et al.   Frontiers in Oncology

Immune microenvironment remodeling after radiation of a progressing brain metastasis

(2023) William H. Hudson et al.   Cell Reports Medicine

Toxicity and outcomes of melanoma brain metastases treated with stereotactic radiosurgery: the risk of subsequent symptomatic intralesional hemorrhage exceeds that of radiation necrosis

(2023) Paola A. Jablonska et al.   JOURNAL OF NEURO-ONCOLOGY

Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial

(2023) Mehmet Altan et al.   Journal for ImmunoTherapy of Cancer

Radiation necrosis in renal cell carcinoma brain metastases treated with checkpoint inhibitors and radiosurgery: An international multicenter study

(2022) Eric J. Lehrer et al.   CANCER

Radiation Therapy for Brain Metastases: ASCO Guideline Endorsement of ASTRO Guideline

(2022) David Schiff et al.   JOURNAL OF CLINICAL ONCOLOGY

Oncologic Outcome and Immune Responses of Radiotherapy with Anti-PD-1 Treatment for Brain Metastases Regarding Timing and Benefiting Subgroups

(2022) Maike Trommer et al.   Cancers

Concurrent Administration of Immune Checkpoint Inhibitors and Stereotactic Radiosurgery Is Well-Tolerated in Patients With Melanoma Brain Metastases: An International Multicenter Study of 203 Patients

(2022) Eric J. Lehrer et al.   NEUROSURGERY

Immunotherapy as Single Treatment for Non-small-cell Lung Cancer Patients with Brain Metastases: a systematic review and meta-analysis – the META-L-BRAIN study.

(2021) Viviane T. Loiola de Alencar et al.   Journal of Thoracic Oncology

Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline

(2021) Michael A. Vogelbaum et al.   JOURNAL OF CLINICAL ONCOLOGY

Radiotherapy‐immunotherapy combinations: perspectives and challenges

(2020) Michele Mondini et al.   Molecular Oncology

Single- and Multifraction Stereotactic Radiosurgery Dose/Volume Tolerances of the Brain

(2020) Michael T. Milano et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Technical Principles and Clinical Workflow of Transcranial MR-Guided Focused Ultrasound

(2020) Ying Meng et al.   STEREOTACTIC AND FUNCTIONAL NEUROSURGERY

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

(2018) Hussein A. Tawbi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: An international meta-analysis of individual patient data

(2018) Eric J. Lehrer et al.   RADIOTHERAPY AND ONCOLOGY

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE